We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01078922
Recruitment Status : Terminated (Study terminated due to slow acrual)
First Posted : March 2, 2010
Results First Posted : May 2, 2014
Last Update Posted : July 16, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Patients will receive weekly infusions of Ofatumumab of 1000 mg each for 8 weeks (induction phase) followed by continuing the study drugs every other week in subsequent cycles (maintenance phase). Each 4 weeks of therapy will be calculated as one cycle. Treatment will continue until disease progression, toxicity, patient's withdrawal, or investigator's discretion.

Condition or disease Intervention/treatment Phase
Non-Hodgkin Lymphomas Drug: Ofatumumab Phase 2

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label Study of Single Agent Ofatumumab in Patients With Relapsed and/or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Study Start Date : February 2010
Primary Completion Date : October 2013
Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma
Drug Information available for: Ofatumumab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Ofatumumab
The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
Drug: Ofatumumab
The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
Other Name: OFT113588

Outcome Measures

Primary Outcome Measures :
  1. Overall Response (OR) [ Time Frame: evaluated every 2 months up to 80 weeks ]

    OR = # of patients with a Complete Response (CR) plus # of patients with a Partial Response (PR) divided by the total # of evaluable patients.

    A CR is defined as:

    1. Disappearance of all disease.
    2. If nodal masses that Positron Emission Tomography (PET)- positive prior to therapy; they must be PET negative
    3. If the nodal masses were Variably or PET negative; they must regress to normal.
    4. No palpable liver or spleen
    5. Palpable nodal masses are no longer palpable
    6. Negative bone marrow biopsy

    A PR is defined as:

    1. Regression of measurable disease and no new sites of disease.
    2. > 50% decrease in Sum of Product of Diameters (SPD) of up to 6 largest masses with no increase in the size of other nodes. If the nodal masses were PET positive prior to therapy then PET positive at previously involved sites is allowed. If they were Variably or PET negative then regression on CT is required.
    3. No increase in the size of the liver or spleen

Secondary Outcome Measures :
  1. Overall Clinical Benefit (OCB) [ Time Frame: Evaluated every 2 cycles (every 2 months), up to 80 weeks ]

    OCB = # patients with a CR + # of patients with a PR + # patients with Stable Disease (SD) divided by the number of evaluable patients CR and PR is defined in Outcome Measure #1

    SD is defined as:

    1. Failure to attain CR/PR or Progressive Disease (PD)
    2. PET remains positive.

    PD is defined as:

    1. Any new lesion > 1.5 cm in longest axis
    2. An increase 50% or more of previously involved sites from nadir
    3. 50% increase in SPD of more than one node or 50% increase in the longest diameter of a previously identified node that is > 1 cm in shortest axis
    4. PET remains positive if it was positive before therapy.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed and/or refractory DLBCL,not HSCT candidates. Pts must have failed standard of care (SOC) therapy w/rituximab plus CHOP or its equivalent & not considered hematopoietic stem cell transplant (HSCT) candidates based on investigator's discretion
  • Pts must have measurable disease radiographically on CT and/or PET scans and/or bone marrow biopsy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Age ≥18 years. No upper limit of age
  • Life expectancy of 6 months or more based on investigator's best estimate.
  • Pts able to read, understand, & sign informed consent
  • Evidence of CD20 positivity in treated pts, using flow or immunohistochemistry.
  • Pts will be stratified based on bulk of disease (bulk defined as any area w/ more than 5cm in greatest dimension)
  • Pts must agree to an acceptable form of birth control

Exclusion Criteria:

  • Other histologies of non-Hodgkin's lymphoma (NHL)
  • Known central nervous system (CNS) involvement with NHL
  • Known HIV positive status
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
  • Corticosteroid use is allowed as long as it is for non-lymphoma related causes such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD).
  • Pts w/prior malignancies are allowed as long as they are in remission & their last treatment for such malignancy is 2 years prior to enrollment or more. Pts w/non-melanoma skin cancers that have received adequate therapy prior to enrollment & women w/history of cervical cancers are allowed.
  • Significant concurrent uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurologic, cerebral, or psychiatric disease.
  • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease per the investigator's assessment).
  • Adequate bone marrow function by virtue of having Platelets >50,000/ul & absolute neutrophil count (ANC) >1000/ul is required unless low counts are attributed to diffuse bone marrow infiltration with NHL as documented with a bone marrow biopsy exam.
  • Pts with creatinine >2.0 times the upper limit of normal will be excluded unless they have a normal creatinine clearance-estimated or measure 12 or 24 hour creatinine clearance of <60 mL/min
  • Pts w/total bilirubin >1.5 times upper limit of normal will be excluded, unless due to DLBCL involvement of liver or a known history of Gilbert's disease.
  • Pts with aspartate aminotransferase (AST)/alanine aminotransferase (ALT)/Alkaline phosphatase (Alk Phos) >2.5 times upper limit of normal
  • Previous tx with Ofatumumab
  • Prior exposure to an investigational agent within 4-weeks from starting Ofatumumab
  • History of significant cerebrovascular disease or event w/significant symptoms or sequelae
  • Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to randomization, congestive heart failure (NYHA III-IV), & arrhythmia unless controlled by therapy, w/exception of extra systoles or minor conduction abnormalities.
  • Positive serology for hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive & regardless of HBsAb status, a HB DNA test will be performed and if positive the subject to be excluded. Note: If HBcAb positive and HBsAb positive, which is indicative of a past infection, subject can be included
  • Positive serology for hepatitis C (HC) defined as a positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result.
  • Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test at screening, including women whose last menstrual period was less than 1 year prior to screening, unable or unwilling to use adequate contraception from study start to 1 year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01078922

United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Oncology Specialists, S.C
Niles, Illinois, United States, 60714
Oncology Specialists, S.C.
Park Ridge, Illinois, United States, 60068
Sponsors and Collaborators
Oncology Specialists, S.C.
University of Illinois at Chicago
Principal Investigator: Chadi Nabhan, MD Oncology Specialists, S.C.
More Information

Responsible Party: Dr. Sigrun Hallmeyer, Principal Investigator, Oncology Specialists, S.C.
ClinicalTrials.gov Identifier: NCT01078922     History of Changes
Other Study ID Numbers: OFT113588 (0908)
First Posted: March 2, 2010    Key Record Dates
Results First Posted: May 2, 2014
Last Update Posted: July 16, 2014
Last Verified: July 2014

Keywords provided by Dr. Sigrun Hallmeyer, Oncology Specialists, S.C.:
ofatumumab diffuse B cell non hodgkins lymphoma DLBCL
refractory DLBCL
relapsed DLBCL

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs